

## ABSTRACT

The present invention relates to a novel method for treating a patient that has osteoporosis and the patient may be having administered cyclase activating parathyroid hormone (CAP) or analogues. The patient receives an administration of a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH<sub>2-84</sub>]) and (SEQ ID No. 2 [PTH<sub>34-84</sub>]), (preferably (SEQ ID No.3 [PTH<sub>3-84</sub>]) and (SEQ ID No. 4 [PTH<sub>28-84</sub>])), or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP, and yet, through a CAP rebound effect, is effective in itself in the treatment of osteoporosis.

2007-03-04 14:03:56